Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Levodopa–entacapone–carbidopa intestinal gel : Data from the Swedish national registry for Parkinson's disease

Öthman, Mezin ; Bergquist, Filip ; Odin, Per LU orcid ; Scharfenort, Monica LU ; Johansson, Anders ; Markaki, Ioanna ; Svenningsson, Per ; Dizdar, Nil and Nyholm, Dag LU (2025) In European Journal of Neurology 32(1).
Abstract

Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking. Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden. Methods: Real-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022. Results: A total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range:... (More)

Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking. Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden. Methods: Real-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022. Results: A total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43–86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device-assisted therapy, mostly LCIG (39 patients). Reported complications were mainly related to PEG-J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG. The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p-Hcy during LECIG was 12 (4.6) μmol/L (n = 44). The median (IQR) PDQ-8 summary index during LECIG was 31 (17) (n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) (n = 41). Conclusions: Data from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device-aided therapy for advanced PD. However, the long-term efficacy and tolerability of LECIG need to be further investigated.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; and
organization
publishing date
type
Contribution to journal
publication status
published
subject
keywords
levodopa, Parkinson's disease, registries, Sweden
in
European Journal of Neurology
volume
32
issue
1
article number
e16582
publisher
Wiley-Blackwell
external identifiers
  • pmid:39625298
  • scopus:85211161674
ISSN
1351-5101
DOI
10.1111/ene.16582
language
English
LU publication?
yes
id
6657d0d1-adc2-48dd-93d0-5fc00f561517
date added to LUP
2025-03-04 14:30:23
date last changed
2025-04-29 18:47:05
@article{6657d0d1-adc2-48dd-93d0-5fc00f561517,
  abstract     = {{<p>Background: Levodopa–entacapone–carbidopa intestinal gel (LECIG) was introduced on the Swedish market in 2019. The therapy is aimed at patients with Parkinson's disease (PD) with fluctuations and dyskinesias. Long-term efficacy and safety data are lacking. Objective: To investigate the efficacy, tolerability, and safety of LECIG in regular clinical practice for Parkinson's disease in Sweden. Methods: Real-world data were collected from the Swedish registry for Parkinson's disease (ParkReg) for all patients reported to receive LECIG during the period from 2019 until 31 August 2022. Results: A total of 150 patients were identified. Sixty-one (41%) of 150 patients were females. At the start of treatment, the median age was 73 years (range: 43–86). The median duration since motor symptoms onset was 17 years (IQR: 9). Fifty (33%) of 150 patients switched from another device-assisted therapy, mostly LCIG (39 patients). Reported complications were mainly related to PEG-J tube and stoma (30%). Twenty (13.3%) of 150 patients discontinued LECIG and 11 (7.3%) patients died while on LECIG. The Parkinson KinetiGraph scores for bradykinesia, dyskinesia, fluctuations, tremor, and immobility for 53 patients during LECIG showed good therapy control. The median (IQR) p-Hcy during LECIG was 12 (4.6) μmol/L (n = 44). The median (IQR) PDQ-8 summary index during LECIG was 31 (17) (n = 52). The median (IQR) EQ5D during LECIG was 0.62 (0.32) (n = 41). Conclusions: Data from ParkReg covering 150 patients over 3 years show LECIG to be an effective and safe device-aided therapy for advanced PD. However, the long-term efficacy and tolerability of LECIG need to be further investigated.</p>}},
  author       = {{Öthman, Mezin and Bergquist, Filip and Odin, Per and Scharfenort, Monica and Johansson, Anders and Markaki, Ioanna and Svenningsson, Per and Dizdar, Nil and Nyholm, Dag}},
  issn         = {{1351-5101}},
  keywords     = {{levodopa; Parkinson's disease; registries; Sweden}},
  language     = {{eng}},
  number       = {{1}},
  publisher    = {{Wiley-Blackwell}},
  series       = {{European Journal of Neurology}},
  title        = {{Levodopa–entacapone–carbidopa intestinal gel : Data from the Swedish national registry for Parkinson's disease}},
  url          = {{http://dx.doi.org/10.1111/ene.16582}},
  doi          = {{10.1111/ene.16582}},
  volume       = {{32}},
  year         = {{2025}},
}